The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Tisotumab vedotin

Geo Regions

Tisotumab vedotin

Overview + Rationale

  • Tisotumab vedotin is an antibody-drug conjugate directed to tissue factor (TF), a protein that is highly prevalent in cervical cancer and many solid tumors. TF promotes cancer growth and metastasis and is associated with poor prognosis1-4​ 
  • In normal physiology, TF initiates the coagulation cascade after vascular injury5,6 
  • In tumor cells, TF has been shown to promote tumor growth, angiogenesis, and metastasis5,6 TF is prevalent in several solid tumors, including cervical cancer and head and neck cancers7,8 

  • In these tumors, where TF is present, levels are elevated relative to normal tissue 2,4 


    Partner: Genmab A/S

Mechanism of Action

Stage of Development

Tisotumab vedotin is being investigated in the tumor types shown below. Safety and efficacy for the uses listed below have not been established.

Small icon representing Other Cancer in dark blue
Recurrent or Metastatic Cervical Cancer
Phase 1b/2 Monotherapy and Combination*

Phase 3 Monotherapy
Small icon representing Early Solid Tumors in green
Advanced Solid Tumors
Phase 2 Monotherapy and Combination

*Closed to Enrollment

REFERENCES: 1. Pan L. Mol Med Rep. 2019: 2077-86; 2. Cocco E. BMC Cancer. 2011: 263; 3. Breij EC. Cancer Res. 2014: 1214-26; 4. Cocco E. Clin Exp Metastasis. 2011: 689-700; 5. Forster Y. Clin Chim Acta. 2006: 12-21; 6. van den Berg YW. Blood. 2012: 924-32; 7. Kaido. Hepatogastroenterology. 2005;52(65): 1383-7; 8. Poon. Clin Cancer Res. 2003;9(14): 5339-45; 9. NCT03786081. https://clinicaltrials.gov/study/NCT03786081; Accessed February 25, 2024; 10. NCT04697628. https://clinicaltrials.gov/study/NCT04697628; Accessed February 25, 2024; 11. NCT03485209. https://clinicaltrials.gov/study/NCT03485209 Accessed February 25, 2024